Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 34Leiomyoma 12Menorrhagia 5Endometriosis 4Myofibroma 3Prostate Adenocarcinoma 2Pregnancy Complications 2Adenocarcinoma 2Uterine Neoplasms 1Uterine Hemorrhage 1Pathologic Complete Response 1Neoplasm, Residual 1Neoplasm Metastasis 1Myoma 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-Resistant Prostate Cancer 1Hormone Treatment-naïve Participants With Prostate Cancer 1

Interventions

Cyclophosphamide 23blinatumomab 18Cytarabine 16fludarabine 13Azacitidine 12venetoclax 10fludarabine phosphate 10Rituximab 8Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Daunorubicin 7Mercaptopurine 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Idarubicin 4Etoposide 4Drug Therapy 4Busulfan 4pembrolizumab 3obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm, Residual × relugolix × Clear all
NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

University of Oklahoma

Phase 1 Recruiting
46 enrolled

Pathologic Complete Response, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡